Enfortumab Vedotin
Drug timelines are a Plus or Pro feature.
20 regulatory and trial events tracked for Enfortumab Vedotin, covering 2023-09-13 to 2026-06-04. Get the full timeline:
Most recent: Clinical Trial Update: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin [Phase 3]